The role of niraparib for the treatment of ovarian cancer

被引：11
作者：
Ethier, Josee-Lyne [1 ,2 ]
Lheureux, Stephanie [3 ,4 ]
Oza, Amit M. [3 ,4 ]
机构：
[1] Canc Ctr Southeastern Ontario, Dept Med Oncol, Kingston, ON, Canada
[2] Queens Univ, Kingston, ON, Canada
[3] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[4] Univ Toronto, Dept Med, Toronto, ON, Canada
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 25期
关键词：
BRCA mutations; homologous repair deficiency; maintenance therapy; MK-4827; niraparib; ovarian cancer; PARP inhibitor; PARP INHIBITOR; HOMOLOGOUS RECOMBINATION; DOUBLE-BLIND; EPITHELIAL OVARIAN; MAINTENANCE THERAPY; DNA-REPAIR; PLATINUM; OLAPARIB; CHEMOTHERAPY; COMBINATION;
D O I：
10.2217/fon-2018-0101
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Epithelial ovarian cancer (EOC) remains a leading cause of cancer death in women. Approximately 10-15% of patients with EOC harbor a genetic predisposition due to mutations in BRCA1/2 genes. In the recurrent setting, prolonging time to platinum-resistance may improve progression-free survival. In BRCA1/2 mutated ovarian cancer, the use of a polyadenosine diphosphate-ribose polymerase inhibitors has been studied in the maintenance and recurrent setting. In the pivotal Phase III NOVA trial, maintenance therapy post platinum response with niraparib significantly improved outcomes in all subgroups, leading to the first polyadenosine diphosphate-ribose polymerase inhibitors approval by the US FDA in this setting. In this review, we will focus on the role of niraparib in the treatment of EOC.
引用
收藏
页码：2565 / 2577
页数：13
相关论文
共 48 条
  • [1] Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
    Abkevich, V.
    Timms, K. M.
    Hennessy, B. T.
    Potter, J.
    Carey, M. S.
    Meyer, L. A.
    Smith-McCune, K.
    Broaddus, R.
    Lu, K. H.
    Chen, J.
    Tran, T. V.
    Williams, D.
    Iliev, D.
    Jammulapati, S.
    FitzGerald, L. M.
    Krivak, T.
    DeLoia, J. A.
    Gutin, A.
    Mills, G. B.
    Lanchbury, J. S.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 107 (10) : 1776 - 1782
  • [2] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Aghajanian, Carol
    Blank, Stephanie V.
    Goff, Barbara A.
    Judson, Patricia L.
    Teneriello, Michael G.
    Husain, Amreen
    Sovak, Mika A.
    Yi, Jing
    Nycum, Lawrence R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2039 - 2045
  • [3] BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
    Alsop, Kathryn
    Fereday, Sian
    Meldrum, Cliff
    deFazio, Anna
    Emmanuel, Catherine
    George, Joshy
    Dobrovic, Alexander
    Birrer, Michael J.
    Webb, Penelope M.
    Stewart, Colin
    Friedlander, Michael
    Fox, Stephen
    Bowtell, David
    Mitchell, Gillian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) : 2654 - 2663
  • [4] [Anonymous], ZEJULA NIRAPARIB CAP
  • [5] [Anonymous], ZEJULA
  • [6] [Anonymous], OL NEW DRUG APPL APP
  • [7] [Anonymous], PREM APPR BRACANALYS
  • [8] [Anonymous], ANN ONCOLOGY
  • [9] [Anonymous], LYNP REC APPR OV CAN
  • [10] [Anonymous], J CLIN ONCOL S
12345